GT201500001A - Composiciones líquidas orales pediátricas que contienen nepadutant - Google Patents

Composiciones líquidas orales pediátricas que contienen nepadutant

Info

Publication number
GT201500001A
GT201500001A GT201500001A GT201500001A GT201500001A GT 201500001 A GT201500001 A GT 201500001A GT 201500001 A GT201500001 A GT 201500001A GT 201500001 A GT201500001 A GT 201500001A GT 201500001 A GT201500001 A GT 201500001A
Authority
GT
Guatemala
Prior art keywords
compositions containing
liquid compositions
nepadutant
oral pediatric
pharmaceutical compositions
Prior art date
Application number
GT201500001A
Other languages
English (en)
Inventor
Claudia Lewerenz
Reinhard Schmitz
Maria Altamura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201500001A publication Critical patent/GT201500001A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVAS COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN UN ANTAGONISTA DEL RECEPTOR NK2 DE TAQUIQUININA, ES DECIR, NEPADUTANT, MUY LIGERAMENTE SOLUBLE EN SOLUCIONES ACUOSAS. ESTAS COMPOSICIONES FARMACÉUTICAS SON SOLUCIONES ESTABLES, DISEÑADAS PARA LA ADMINISTRACIÓN ORAL DEL INGREDIENTE ACTIVO Y PREFERENTEMENTE DESTINADAS A USO EN NEONATOS E INFANTES PARA TRATAR ENFERMEDADES GASTROINTESTINALES PEDIÁTRICAS
GT201500001A 2012-07-12 2015-01-08 Composiciones líquidas orales pediátricas que contienen nepadutant GT201500001A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000331A ITRM20120331A1 (it) 2012-07-12 2012-07-12 Composizioni pediatriche orali liquide contenenti nepadutant.

Publications (1)

Publication Number Publication Date
GT201500001A true GT201500001A (es) 2015-12-31

Family

ID=46939841

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201500001A GT201500001A (es) 2012-07-12 2015-01-08 Composiciones líquidas orales pediátricas que contienen nepadutant

Country Status (32)

Country Link
US (1) US9421268B2 (es)
EP (1) EP2872137A1 (es)
JP (1) JP6014252B2 (es)
KR (1) KR20150030766A (es)
CN (1) CN104507476B (es)
AP (1) AP2015008224A0 (es)
AU (1) AU2013288231B2 (es)
BR (1) BR112015000647A2 (es)
CA (1) CA2878817A1 (es)
CL (1) CL2015000053A1 (es)
CO (1) CO7240380A2 (es)
CR (1) CR20150064A (es)
EA (1) EA025618B1 (es)
EC (1) ECSP15005163A (es)
GE (1) GEP201606586B (es)
GT (1) GT201500001A (es)
HK (1) HK1204920A1 (es)
IL (1) IL236667A0 (es)
IN (1) IN2015DN00966A (es)
IT (1) ITRM20120331A1 (es)
MA (1) MA37845B2 (es)
MX (1) MX2015000491A (es)
NI (1) NI201500001A (es)
NZ (1) NZ703090A (es)
PE (1) PE20150865A1 (es)
PH (1) PH12015500070B1 (es)
SG (1) SG11201500095PA (es)
TN (1) TN2014000515A1 (es)
TW (1) TWI592167B (es)
UA (1) UA112905C2 (es)
WO (1) WO2014009926A1 (es)
ZA (1) ZA201500978B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634413A1 (en) 2017-06-09 2020-04-15 Exelixis, Inc. Liquid dosage forms to treat cancer
WO2024156799A1 (en) * 2023-01-27 2024-08-02 Hyloris Developments Sa Use of vitamin e tpgs as a taste masking agent for bitter drugs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203804A (es) 1987-10-19 1992-07-01 Liposome Co Inc Sistemas farmaceuticos a base de tocoferol.
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
HU215966B (hu) 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
IT1277835B1 (it) 1995-03-13 1997-11-12 Menarini Farma Ind Composti biciclici, loro preparazione ed uso in composizioni farmaceutiche
MY126358A (en) 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
WO1998008490A1 (en) 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
US5891845A (en) 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
DE10111058A1 (de) * 2001-03-08 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten
ITRM20030153A1 (it) 2003-04-03 2004-10-04 Exall S R L Formulazione idrosolubile contenente ubichinone per uso oftalmico.
JP4977611B2 (ja) 2004-09-24 2012-07-18 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 新規な種類の界面活性剤様物質
ITFI20040221A1 (it) * 2004-10-27 2005-01-27 Guidotti & C Spa Composizioni farmaceutiche a base di nk2 antagonisti per uso pediatrico
EP1712220A1 (en) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition

Also Published As

Publication number Publication date
CL2015000053A1 (es) 2015-07-03
ZA201500978B (en) 2017-01-25
CO7240380A2 (es) 2015-04-17
ECSP15005163A (es) 2016-01-29
AP2015008224A0 (en) 2015-01-31
WO2014009926A1 (en) 2014-01-16
NZ703090A (en) 2016-06-24
BR112015000647A2 (pt) 2017-06-27
HK1204920A1 (en) 2015-12-11
IN2015DN00966A (es) 2015-06-12
GEP201606586B (en) 2016-12-12
UA112905C2 (uk) 2016-11-10
MA20150424A1 (fr) 2015-11-30
AU2013288231B2 (en) 2017-06-15
AU2013288231A1 (en) 2015-01-22
TN2014000515A1 (en) 2016-03-30
PE20150865A1 (es) 2015-06-10
ITRM20120331A1 (it) 2014-01-13
CN104507476B (zh) 2017-10-17
PH12015500070A1 (en) 2015-03-16
MA37845B2 (fr) 2017-10-31
KR20150030766A (ko) 2015-03-20
PH12015500070B1 (en) 2015-03-16
US20150165034A1 (en) 2015-06-18
JP6014252B2 (ja) 2016-10-25
US9421268B2 (en) 2016-08-23
TW201408336A (zh) 2014-03-01
IL236667A0 (en) 2015-02-26
JP2015522063A (ja) 2015-08-03
EA025618B1 (ru) 2017-01-30
CN104507476A (zh) 2015-04-08
NI201500001A (es) 2015-09-18
SG11201500095PA (en) 2015-02-27
MX2015000491A (es) 2015-06-03
EA201500128A1 (ru) 2015-05-29
CR20150064A (es) 2015-04-30
CA2878817A1 (en) 2014-01-16
TWI592167B (zh) 2017-07-21
EP2872137A1 (en) 2015-05-20

Similar Documents

Publication Publication Date Title
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
BR112013008005A2 (pt) composição farmacêutica kpiquida pronta para uso para adminidtração parental a um indivíduo
BR112015009228A8 (pt) Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção
CR20120419A (es) Formulación de anticuerpos y regimenes terapéuticos
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
EA201500742A1 (ru) Защищенные от нецелевого использования фармацевтические композиции
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
BR112015030387A2 (pt) compostos de pirazol como moduladores de fshr e usos dos mesmos
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
PH12015500823A1 (en) Modified release formulations for oprozomib
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
TR201819662T4 (tr) Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
GT201500001A (es) Composiciones líquidas orales pediátricas que contienen nepadutant
EA201491614A1 (ru) Способ лечения гинекологических заболеваний
BR112016015175A2 (pt) Formulação farmacêutica, método para a fabricação de uma formulação farmacêutica compreendendo sildenafila e clomipramina e comprimido
EA201590732A1 (ru) Диспергируемая таблетка
EA201500367A1 (ru) Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения цереброваскулярной патологии и нейродегенеративных заболеваний центральной нервной системы
EA201500368A1 (ru) Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора